Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Brase

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancersCarsten Denkert, Gunter von Minckwitz, Jan C Brase, et al.
Nature Cancer|August 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaRenáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Nature Cancer|July 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaRenáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancersCarsten Denkert, Gunter von Minckwitz, Jan C Brase, et al.
Nature Cancer|August 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaRenáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Nature Cancer|July 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaRenáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Pageof 6